Drugs in ATC Class D01BA

Up to Top Level ATC Classes

Up to D - Dermatologicals

Up to D01 - ANTIFUNGALS FOR DERMATOLOGICAL USE

Up to D01B - ANTIFUNGALS FOR SYSTEMIC USE

Drugs in ATC Class: D01BA - Antifungals for systemic use

Tradename	Generic Name
GRIFULVIN V	griseofulvin, microcrystalline
GRIFULVIN V	griseofulvin, microsize
GRISACTIN	griseofulvin, microcrystalline
GRISEOFULVIN	griseofulvin, microsize

D01BA Market Analysis and Financial Projection

The market for ATC Class D01BA antifungals (systemic antifungals targeting dermatological mycoses) demonstrates robust growth driven by rising fungal infections, therapeutic innovations, and strategic patenting practices. Below is an analysis of the market dynamics and patent landscape:

---

Market Dynamics

Growth Projections

• The global antifungal drugs market is projected to reach USD 19.16–24.51 billion by 2030–2034, growing at a CAGR of 3.49%–11.5% [1][5][7].
• Systemic antifungals, including azoles (e.g., terbinafine) and polyenes, dominate due to their efficacy against invasive fungal infections like aspergillosis and candidiasis [3][5].

Key Drivers

1. Rising Fungal Infections:

   • Invasive fungal infections cause 3.8 million annual deaths globally, with aspergillosis mortality rates exceeding 85% [3].
   • Immunocompromised populations (HIV, cancer, transplant patients) drive demand for advanced therapies [7][9].

2. Drug Development Advances:

   • Azoles (e.g., griseofulvin, terbinafine) remain dominant due to broad-spectrum activity, safety, and FDA approvals for new formulations [1][14].
   • Nanoparticle-based delivery systems (e.g., liposomal anidulafungin) enhance drug targeting and reduce toxicity [12].

3. Geographic Trends:

   • North America leads with USD 7.3 billion in 2024, supported by OTC drug availability and high healthcare expenditure [1][5].
   • Asia-Pacific is the fastest-growing market due to improving healthcare infrastructure [5].

---

Patent Landscape

Innovation Trends

1. Combination Therapies:

   • Recent patents focus on synergistic combinations (e.g., azoles + cell-wall-targeting agents) to overcome resistance [10].
   • Example: Astellas Pharma’s patents combine polyenes/azoles with lipopeptides for enhanced efficacy [10].

2. Secondary Patenting:

   • Companies extend market exclusivity through patents for new formulations (e.g., intravenous terbinafine), dosing regimens, or delivery systems [16].
   • Nanoparticle technologies (e.g., antibody-conjugated liposomes) improve drug stability and reduce off-target effects [12].

3. Challenges in Novelty:

   • Over 60% of antifungal patents (2000–2015) involve “me-too” drugs or minor modifications of existing agents (e.g., analogs of terbinafine) [10][16].
   • Regulatory scrutiny is rising to curb pseudo-innovations that inflate prices without clinical benefits [2][10].

Key Players & Strategies

• Merck and Pfizer lead in R&D for next-generation antifungals (e.g., voriconazole, echinocandins) [7].
• Startups focus on AI-driven drug discovery to accelerate candidate screening and reduce development costs [3][9].

---

Future Outlook

• Emerging Technologies: AI and machine learning are revolutionizing antifungal research, with 15% of recent patents leveraging predictive models for drug-target interactions [9][13].
• Regulatory Shifts: Governments are prioritizing reimbursement for high-impact innovations (Category A/B drugs) while curbing payments for low-value derivatives (Category C) [2][5].
• Antimicrobial Resistance: Resistance in Candida and Aspergillus species is driving demand for non-azole alternatives, including antifungal peptides and immunotherapy [9][13].

---

Highlight: “The integration of AI in antifungal drug discovery could reduce development timelines by 40%, offering a $12.2 billion market opportunity by 2030” [9].

This market’s growth hinges on balancing genuine therapeutic innovation with cost containment, ensuring systemic antifungals remain accessible amid rising global health challenges.

References

1. https://www.globenewswire.com/news-release/2024/11/01/2973422/28124/en/Antifungal-Drugs-Market-Projected-to-Reach-USD-19-16-Billion-by-2030-Amid-Rising-Incidence-of-Fungal-Infections-Global-Research-2024.html
2. https://sbc.org.pl/Content/82665/PDF/Aptekarz-2007-03-angielski.pdf?handler=pdf
3. https://www.prophecymarketinsights.com/market_insight/systemic-antifungals-market-5773
4. https://atcddd.fhi.no/atc_ddd_index/?code=D01B&showdescription=yes
5. https://www.precedenceresearch.com/antifungal-drugs-market
6. https://www.doc-developpement-durable.org/file/sante-hygiene-medecine/guides-medicaux/the%20selection%20and%20use%20of%20essential%20medicines%202009%20-%20WHO.pdf
7. https://github.com/waldarolka1j/Market-Research-Report-List-1/blob/main/systemic-antifungals-market.md
8. https://www.sciensano.be/sites/default/files/sciensano_national_report_antimicrobial_consumption_2010-2019_version_20210329.pdf
9. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2020.00105/full
10. https://ri.conicet.gov.ar/bitstream/handle/11336/52761/CONICET_Digital_Nro.f6b17912-5d68-4d9b-a4d7-84934e2ef807_A.pdf?sequence=2&isAllowed=n
11. https://go.drugbank.com/drugs/DB00857
12. https://patents.google.com/patent/US11273124B2/en
13. https://pubmed.ncbi.nlm.nih.gov/36169343/
14. https://go.drugbank.com/drugs/DB00400
15. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.01156/full
16. https://patentpc.com/blog/warding-off-diseases-antifungal-antimicrobial-drug-patents
17. https://en.wikipedia.org/wiki/ATC_code_D01